BioCryst Pharmaceuticals
BCRX
#4741
Rank
A$3.12 B
Marketcap
A$12.24
Share price
3.14%
Change (1 day)
10.74%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of June 2026 : A$1.13 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is A$1.13 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2026)

Total debt by year

Year Total debt Change
2025-12-31A$0.65 B-49.61%
2024-12-31A$1.30 B7.36%
2023-12-31A$1.21 B11.16%
2022-12-31A$1.08 B33.15%
2021-12-31A$0.81 B125.11%
2020-12-31A$0.36 B200.64%
2019-12-31A$0.12 B37.78%
2018-12-31A$87.75 M25.2%
2017-12-31A$70.09 M-5.95%
2016-12-31A$74.53 M79.91%
2015-12-31A$41.42 M13.01%
2014-12-31A$36.65 M8.99%
2013-12-31A$33.63 M16.5%
2012-12-31A$28.86 M-1.33%
2011-12-31A$29.25 M
2000-12-31A$0.01 M
1997-12-31A$0.15 M-59.36%
1996-12-31A$0.37 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Gilead Sciences
GILD
A$37.56 B 3,210.39%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$34.58 B 2,948.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
A$1.49 B 31.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.98 B-12.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$0.42 B-62.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
A$7.01 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
A$2.14 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
A$11.3 M-99.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
A$0.83 B-26.62%๐Ÿ‡บ๐Ÿ‡ธ USA